Nofetumomab merpentan

Nofetumomab Merpentan (also known as Verluma) is a monoclonal antibody designed for the treatment of various types of cancer. It was developed by Pharmacia and later acquired by Novartis.

History[edit | edit source]

Nofetumomab Merpentan was initially developed by Pharmacia, a Swedish pharmaceutical company. After the acquisition of Pharmacia by Pfizer in 2003, the development rights for Nofetumomab Merpentan were transferred to Novartis.

Mechanism of Action[edit | edit source]

Nofetumomab Merpentan is a monoclonal antibody that targets the carcinoembryonic antigen (CEA), a protein often overexpressed in cancer cells. By binding to this antigen, Nofetumomab Merpentan can help the immune system recognize and destroy cancer cells.

Clinical Trials[edit | edit source]

Several clinical trials have been conducted to evaluate the efficacy and safety of Nofetumomab Merpentan in various types of cancer, including non-small cell lung cancer (NSCLC), colorectal cancer, and breast cancer.

Side Effects[edit | edit source]

Like all medications, Nofetumomab Merpentan can cause side effects. The most common side effects reported in clinical trials include nausea, vomiting, and fatigue.

Current Status[edit | edit source]

As of 2021, Nofetumomab Merpentan is not currently approved for use in any country. However, research is ongoing to further evaluate its potential as a cancer treatment.